MedTrace Logo

PillCam® ESO 2 in Esophageal Pathologies

NCT00885469 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 101

Last updated 2019-07-31

No results posted yet for this study

Summary

Study Hypothesis:

* PillCam™ ESO-2 will demonstrate equivalent accuracy parameters as compared to blinded esophagogastroduodenoscopy (EGD) in detecting suspected Barrett's esophagus, detecting and grading esophagitis.
* PillCam™ ESO will demonstrate all safety parameters as compared to EGD
* PillCam™ ESO-2 will demonstrate better patient's satisfaction as compared to EGD

Conditions

  • Barrett's Esophagus
  • Gastroesophageal Reflux Disease

Sponsors & Collaborators

  • Medtronic - MITG

    lead INDUSTRY

Principal Investigators

  • Glen Eisen, MD · Oregon Health and Science University

  • Prateek Sharma, MD · Department of VA Medical Affairs Medical Center of Kansas City

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2009-03-31
Completion
2009-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00885469 on ClinicalTrials.gov